Short-term Prednisone to Treat STA Study(SPTSS) (STA)
Primary Purpose
Subacute Thyroiditis
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Prednisone 1 week
Prednisone 6 weeks
Sponsored by
About this trial
This is an interventional treatment trial for Subacute Thyroiditis focused on measuring Efficacy, safety, short, term, subacute thyroiditis
Eligibility Criteria
Inclusion Criteria:
- 18-70 years patients with Moderate and severe subacute thyroiditis
Exclusion Criteria:
- adrenal cortical dysfunction,
- use of corticosteroids in nearly three months,
- mild subacute thyroiditis,
- non-onset STA,
- family history of diabetes,
- gastric ulcer,
- the special medication history,
- heart,liver and renal insufficiency,
- tumors,
- tuberculosis and
- poor compliance.
Sites / Locations
- The Second Affiliated Hospital, Third Military Medical University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Prednisone 1 week
Prednisone 6 weeks
Arm Description
Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
Outcomes
Primary Outcome Measures
The Efficiency of experimental group comparing with control group during 14 days
We will observe change of erythrocyte sedimentation rate from >20mm/h to normal,C-reactive protein,pain and goiter disappear after 14 days.
Secondary Outcome Measures
recurrence rate
The recurrence will be defined:local tenderness, goiter, inflammatory factors such as erythrocyte sedimentation rate, C-reactive protein increased during 180 days.
hypothyroidism
change in thyroid function:from hyperthyroidism on baseline to hypothyroidism after 180 days.
Adrenal insufficiency after withdraw in experimental group and control group.
The Symptom such as anorexia, nausea, vomiting, abdominal pain, fatigue, weakness, collapse, muscle pain, joint pain, weight loss, orthostatic hypotension, lethargy and depression.
Change of blood glucose in experimental group and control group.
Glucose change when taking medicine:from normal blood glucose on baseline to hyperglycemia at the special time during medication.
Change of blood pressure in experimental and control group during medication.
We will measure blood pressure before and after withdraw prednisone in experimental and control group.
Bone metabolism after withdraw in experimental group and control group.
We will measure Bone metabolism markers before and after withdraw prednisone in experimental and control group.
Change of Lipids in experimental and control group during medication.
We will measure Lipids before and after withdraw prednisone in experimental and control group.
Full Information
NCT ID
NCT01837433
First Posted
April 6, 2013
Last Updated
May 18, 2015
Sponsor
Xinqiao Hospital of Chongqing
1. Study Identification
Unique Protocol Identification Number
NCT01837433
Brief Title
Short-term Prednisone to Treat STA Study(SPTSS)
Acronym
STA
Official Title
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Xinqiao Hospital of Chongqing
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis
The investigators hypothesize that less adverse reactions will be observed, comparing with the guidelines recommend. The recurrence rate, adrenal insufficiency, temporary and permanent hypothyroidism aren't significant difference.
Detailed Description
Comparing with the guidelines recommend, short-term (one week)prednisone and nsaids following up next week to treat moderate and severe subacute thyroiditis will be assessed.
The patients in wards will be assessed from temperature,erythrocyte sedimentation rate,C-reactive protein,local pain and goiter.The random treatment will be executed in moderate and severe SAT after informed consent be signed.
Subjects will be monitored once every 2 weeks.If patients complained of pain in their neck or if the erythrocyte sedimentation rate is still high,after discontinuation of prednisone, prednisone treatment will be resumed in moderate and severe subject and non-steroidal anti-inflammatory drugs will be used in mild subject.Anti-ulcer drugs will be administered to all patients.
The endpoint of the study are efficiency and safety of short-term prednisone treating. The investigators will assess adrenal insufficiency (such as anorexia, nausea, vomiting, abdominal pain),steroid withdrawal syndrome, recurrence rate and hypothyroidism. The investigators will observe erythrocyte sedimentation rate,pain,steroid level and thyroid function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subacute Thyroiditis
Keywords
Efficacy, safety, short, term, subacute thyroiditis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Prednisone 1 week
Arm Type
Experimental
Arm Description
Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
Arm Title
Prednisone 6 weeks
Arm Type
Active Comparator
Arm Description
Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
Intervention Type
Drug
Intervention Name(s)
Prednisone 1 week
Other Intervention Name(s)
Glucocorticoid
Intervention Description
Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
Intervention Type
Drug
Intervention Name(s)
Prednisone 6 weeks
Other Intervention Name(s)
Glucocorticoid
Intervention Description
Guidelines recommend
Primary Outcome Measure Information:
Title
The Efficiency of experimental group comparing with control group during 14 days
Description
We will observe change of erythrocyte sedimentation rate from >20mm/h to normal,C-reactive protein,pain and goiter disappear after 14 days.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
recurrence rate
Description
The recurrence will be defined:local tenderness, goiter, inflammatory factors such as erythrocyte sedimentation rate, C-reactive protein increased during 180 days.
Time Frame
180 days
Title
hypothyroidism
Description
change in thyroid function:from hyperthyroidism on baseline to hypothyroidism after 180 days.
Time Frame
180 days
Title
Adrenal insufficiency after withdraw in experimental group and control group.
Description
The Symptom such as anorexia, nausea, vomiting, abdominal pain, fatigue, weakness, collapse, muscle pain, joint pain, weight loss, orthostatic hypotension, lethargy and depression.
Time Frame
42 days
Title
Change of blood glucose in experimental group and control group.
Description
Glucose change when taking medicine:from normal blood glucose on baseline to hyperglycemia at the special time during medication.
Time Frame
42 days
Title
Change of blood pressure in experimental and control group during medication.
Description
We will measure blood pressure before and after withdraw prednisone in experimental and control group.
Time Frame
42 days
Title
Bone metabolism after withdraw in experimental group and control group.
Description
We will measure Bone metabolism markers before and after withdraw prednisone in experimental and control group.
Time Frame
42 days
Title
Change of Lipids in experimental and control group during medication.
Description
We will measure Lipids before and after withdraw prednisone in experimental and control group.
Time Frame
42 days
Other Pre-specified Outcome Measures:
Title
Other side effects of prednisone
Description
Such as,cushing appearance; female hirsutism, menstrual disorders, impotence in men; gastrointestinal ulcers; psychiatric symptoms: anxiety, agitation, fatigue
Time Frame
42 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18-70 years patients with Moderate and severe subacute thyroiditis
Exclusion Criteria:
adrenal cortical dysfunction,
use of corticosteroids in nearly three months,
mild subacute thyroiditis,
non-onset STA,
family history of diabetes,
gastric ulcer,
the special medication history,
heart,liver and renal insufficiency,
tumors,
tuberculosis and
poor compliance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hongting Zheng, Ph.D
Organizational Affiliation
Department of Endocrinology, The Second Affiliated Hospital, Third Military Medical University, Chongqing, People's Republic of China.
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Second Affiliated Hospital, Third Military Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400037
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
23227861
Citation
Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid. 2013 Mar;23(3):269-72. doi: 10.1089/thy.2012.0459.
Results Reference
result
PubMed Identifier
12727961
Citation
Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003 May;88(5):2100-5. doi: 10.1210/jc.2002-021799.
Results Reference
result
PubMed Identifier
18421188
Citation
Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, Ito M, Kubota S, Fukata S, Miyauchi A. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med. 2008;47(8):725-9. doi: 10.2169/internalmedicine.47.0740. Epub 2008 Apr 16.
Results Reference
result
PubMed Identifier
21510801
Citation
Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun;21(6):593-646. doi: 10.1089/thy.2010.0417. Epub 2011 Apr 21. Erratum In: Thyroid. 2011 Oct;21(10):1169. Thyroid. 2012 Nov;22(11):1195.
Results Reference
result
PubMed Identifier
19337012
Citation
Nishihara E, Amino N, Ohye H, Ota H, Ito M, Kubota S, Fukata S, Miyauchi A. Extent of hypoechogenic area in the thyroid is related with thyroid dysfunction after subacute thyroiditis. J Endocrinol Invest. 2009 Jan;32(1):33-6. doi: 10.1007/BF03345675.
Results Reference
result
PubMed Identifier
8636251
Citation
Iitaka M, Momotani N, Ishii J, Ito K. Incidence of subacute thyroiditis recurrences after a prolonged latency: 24-year survey. J Clin Endocrinol Metab. 1996 Feb;81(2):466-9. doi: 10.1210/jcem.81.2.8636251.
Results Reference
result
PubMed Identifier
4098399
Citation
Vagenakis AG, Abreau CM, Braverman LE. Prevention of recurrence in acute thyoiditis following corticosteroid withdrawal. J Clin Endocrinol Metab. 1970 Dec;31(6):705-8. doi: 10.1210/jcem-31-6-705. No abstract available.
Results Reference
result
PubMed Identifier
8257868
Citation
Volpe R. The management of subacute (DeQuervain's) thyroiditis. Thyroid. 1993 Fall;3(3):253-5. doi: 10.1089/thy.1993.3.253.
Results Reference
result
PubMed Identifier
12826640
Citation
Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003 Jun 26;348(26):2646-55. doi: 10.1056/NEJMra021194. No abstract available. Erratum In: N Engl J Med. 2003 Aug 7;349(6):620.
Results Reference
result
PubMed Identifier
19138419
Citation
Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J. 2009 Jan 12;6:5. doi: 10.1186/1743-422X-6-5.
Results Reference
result
PubMed Identifier
11334386
Citation
Mizukoshi T, Noguchi S, Murakami T, Futata T, Yamashita H. Evaluation of recurrence in 36 subacute thyroiditis patients managed with prednisolone. Intern Med. 2001 Apr;40(4):292-5. doi: 10.2169/internalmedicine.40.292.
Results Reference
result
PubMed Identifier
17923793
Citation
Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest. 2007 Sep;30(8):631-5. doi: 10.1007/BF03347442.
Results Reference
result
PubMed Identifier
8388401
Citation
Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab. 1993 May;76(5):1188-91. doi: 10.1210/jcem.76.5.8388401.
Results Reference
result
PubMed Identifier
18535733
Citation
Alves C, Robazzi TC, Mendonca M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008 May-Jun;84(3):192-202. doi: 10.2223/JPED.1773.
Results Reference
result
PubMed Identifier
10517721
Citation
Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999 Aug 18;282(7):671-6. doi: 10.1001/jama.282.7.671. No abstract available.
Results Reference
result
PubMed Identifier
10683005
Citation
Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000 Feb 12;355(9203):542-5. doi: 10.1016/S0140-6736(99)06290-X.
Results Reference
result
PubMed Identifier
18000630
Citation
Longui CA. Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S163-77. doi: 10.2223/JPED.1713. Epub 2007 Nov 14.
Results Reference
result
Learn more about this trial
Short-term Prednisone to Treat STA Study(SPTSS)
We'll reach out to this number within 24 hrs